News & Updates

For atrial fibrillation (AF) patients with normal or impaired renal function, use of nonvitamin K antagonist oral anticoagulants (NOACs) results in improved outcomes relative to vitamin K antagonist (VKA) therapy, suggests a study presented at ESC 2024.

Postmenopausal women who use menopausal hormone therapy (MHT) appear to have increased Lactobacillus abundance and lower vaginal microbial community diversity, according to a study.

The novel oral corticotropin-releasing factor type 1 receptor antagonist crinecerfont helps supress androstenedione levels in children with congenital adrenal hyperplasia (CAH) and reduce the need for glucocorticoids, as shown in the phase III CAHtalyst Pediatric trial.

Users of glucagon-like peptide-1 (GLP-1) receptor agonists, most of whom have type 2 diabetes, are not at increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders, as shown in a study.

Treatment with vedolizumab and antitumour necrosis factor-α agents provides clinical benefits, with an acceptable safety profile, in patients with steroid-refractory microscopic colitis (MC), suggests a study.

Adjunctive brivaracetam (BRV) reduces seizure frequency and improves response in Asian adults with uncontrolled focal-onset seizures (FOS), findings from the phase III therapeutic confirmatory EP0083 study suggest.